Company intelligence / Profile preview

CEL-SCI Corporation

Ownership: Public · CVM
Development stage: Phase 3

Overview

CEL-SCI Corporation is a biotechnology company focused on researching and developing immunotherapy for the treatment of cancer and other diseases. Their lead product, Multikine (Leukocyte Interleukin, Injection), has completed a Phase 3 clinical trial for the treatment of advanced primary head and neck cancer.

Modalities: Immunotherapy (biological
Industry: Biotech

Drug pipeline

11 assets

leukocyte interleukin

10 more assets in the full pipeline.

Financials

Market cap: $24.1M
Total revenue: $0
Enterprise value: $25.5M

Beyond the preview

Go deeper on CEL-SCI Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEL-SCI Corporation.